Linlin Wu

Linlin Wu

Auto-generated profile, based on publicly available information

Linlin Wu

Department of Nephrology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2021 in Nephrology
Verified
Journal Article
Closed access
PDF file
RLRumei Luan
Rumei Luan
GTGeng Tian
Geng Tian
XCXin Ci
Xin Ci
QZQian Zheng
Qian Zheng
LWLinlin Wu
Linlin Wu
XLXuehong Lu
Xuehong Lu


8 March 2022 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
MWMan Wu
Man Wu
QGQiaoyan Guo
Qiaoyan Guo
XLxianjun liu
xianjun liu
LWLinlin Wu
Linlin Wu
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma and has a poor prognosis. However, its underlying mechanisms remain unclear. The present study aimed to evaluate the role of small proline‑rich repeat protein 3 (SPRR3) in the proliferation, migration and invasion of ccRCC cells and to investigate its upstream and downstream regulatory mechanisms. Survival analysis was performed using the UALCAN website based on the The Cancer Genome Atlas database. Normal renal cell line HK‑2 and ccRCC cell lines (786‑O, CaKi‑1 and UMRC‑2) were used. Reverse transcription‑quantitative PCR (RT‑qPCR) was used to detect mRNA and microRNA (miRNA) levels. Western blotting was used to detect protein levels. Cell Counting Kit‑8 and colony formation assays, a wound healing assay and a Transwell invasion assay were used to assess the proliferation, migration and invasion of ccRCC cells, respectively. Transfection of overexpression plasmids and small interfering RNAs were used to upregulate and knockdown SPRR3 expression, respectively. Transfection of miRNA‑mimics was used to overexpress miR‑338‑3p. A luciferase reporter gene assay was used to verify the predicted binding relationship between SPRR3 mRNA and miR‑338‑3p. The results indicated the following: i) SPRR3 was a risk factor for the survival of patients with ccRCC, and was upregulated in ccRCC cell lines; ii) SPRR3 promoted the proliferation, migration and invasion of ccRCC cells; iii) SPRR3 regulated the tumor phenotypes of ccRCC cells via the PI3K/Akt pathway; iv) miR‑338‑3p directly targeted SPRR3 mRNA and negatively regulated SPRR3 expression; and v) miR‑338‑3p inhibited the PI3K/Akt pathway and the tumor phenotypes of ccRCC cells by downregulating SPRR3. In conclusion, SPRR3, as a novel target of miR‑338‑3p, regulated the proliferation, migration and invasion of ccRCC cells via the PI3K/Akt pathway; this finding not only enriches our understanding of the mechanism underlying ccRCC development, but also demonstrates a potential novel therapeutic target for this disease.

1 March 2015 in International Journal of Mycobacteriology
Verified
Journal Article
Open access
YHYi Hu
Yi Hu
LWLinlin Wu
Linlin Wu
BXBiao Xu
Biao Xu
BackgroundContinuous understanding of the epidemiology of drug resistant TB, especially for multidrug/extensively drug resistant TB (MDR/XDR-TB) is essential to develop the appropriate strategies for preventing its epidemic. The present study aimed to investigate the longitudinal trend of the rates and dynamic change of MDR/XDR M.Tuberculosis and its transmission pattern to adjust the TB control activities in eastern rural China.MethodsThe data presented here spanned 8years and was derived from three population-based studies of drug-resistant TB in two eastern rural counties: DQ and GY in terms of socio-demographic characteristics of drug-resistant cases, as well as the microbiological and molecular features of their infected M.Tuberculosis strains in eastern rural China.ResultsOf the 990 smear-positive patients within the studied period, 413 (41.7%) cases showed resistance to any of the detected first- (INH, RIF and EMB) and second-line (OFL, LEV, KAN, AMK, and CAP) anti-TB drugs: 89 with MDR (9.0%). Of these MDR-TB isolates, 34 cases (38.2%) showed resistance to any of the second-line anti-TB drugs: 25 (28.1%) with resistance either to FQs or second-line injective drugs (Pre-XDR) and 9 (10.1%) showed simultaneous resistance to the two categories (XDR). Molecular analysis of pncA gene revealed 185 M.Tuberculosis cases contained the mutation associated with PZA resistance, with a significantly higher proportion in MDR compared with the others (35% vs. 16.8%, p=0.04). For the longitudinal perspective, MDR-TB (from 9.1% to 14.5%, p=0.001), Pre-XDR-TB (from 2.5% to 4.5%, p=0.01) and XDR-TB (from 0.9% to 3.6%, p=0.04) exhibited an upward trend, while there was a significant decreasing change in the proportion of totally first-line drug sensitivity (p=0.047). Non-linear regression analysis showed that MDR-TB, Pre-XDR-TB and XDR-TB increased significantly over the study period with a double time of 4.8year (95% CI: 3.69–5.92), 3.2year (95% CI: 2.16–5.94) and 3.3year (95% CI: 1.099–8.32). Being clustered, sputum smear result and previously treated history were factors increasing the trending of M/XDR-TB. The MIRU24 loci genotyping revealed the 21 clusters involving 48 (28.4%) drug-resistant cases in DQ and 28 clusters involving 59 (32.1%) drug-resistant cases in GY. Of these clusters, 11 were related to MDR/XDR-TB and 8 of these clustered genotypes were observed more than 5years of the study period.ConclusionThese results show that active transmission of MDR/XDR-TB is taking place and that the increasing trend in the observed rate of MDR/XDR-TB tends to be due to the variation in the distribution of patients with different socio-demographic features and the continued transmission of particular genetic clusters. Continuous surveillance of clinical isolates of M.Tuberculosis is needed to identify M/XDR-TB, especially in patients who have a history of TB and have received prior anti-TB treatment